The ability of the body to perceive noxious stimuli lies in a heterogeneous group of primary somatosensory neurons termed nociceptors. The molecular receptors of noxious mechanical, temperature, or chemical stimuli are expressed in these neurons and have drawn considerable attention as possible targets for analgesic development to improve treatment for the millions who suffer from chronic pain conditions. A number of thermoTRPs, a subset of the transient receptor potential family of ion channels, are activated by a wide range on noxious stimuli. In this review, we review the function of these channels and examine the evidence that thermoTRPs play a vital role in acute, inflammatory and neuropathic nociception.
Introduction
The capacity to feel pain is normally advantageous, providing powerful motivation to withdraw from noxious stimuli, to guard injured tissue, and to avoid dangerous environments in the future. However, acute and chronic pain affects hundreds of millions of people and imposes a severe emotional and economic burden on both individuals and society as a whole. Pain is the number one reason for seeking medical care in the United States. It is a major symptom in many illnesses and can be particularly debilitating when it becomes disassociated with initial injury or illness entering a chronic phase in which pain itself become the disease. In such cases, pain is often felt seemingly in the absence of noxious stimuli, or by a lowering of the threshold of stimuli to induce pain such that an innocuous stimulus can trigger pain (allodynia) or that a noxious stimulus evokes a heightened sensation of pain (hyperalgesia).
Pain is a complex phenomenon involving multiple ascending and descending neuronal pathways and complex processing within the brain. Potential targets for therapeutic intervention can occur anywhere throughout the pain system. Many analgesic targets are expressed in central nervous system (CNS) pain circuits. However, because of the widespread expression of targets in other neural pathways and tissues, analgesic administration often causes deleterious side effects. For example, analgesics that act on opioid receptors suppress neuronal activity within the pain pathway but also can evoke euphoria, dependency, sedation, constipation, and suppression of respiration. One avenue for the development of analgesics with the potential for fewer side effects has been to identify targets that are mainly expressed within the pain pathway.
Molecules that regulate the activity of peripheral neurons (nociceptors) that respond to noxious mechanical, thermal, and chemical stimuli are strong candidates for therapeutic intervention. Nociceptors (classified as small diameter unmyelinated C-fibers or lightly myelinated small diameter Aδ fibers) have cell bodies located in the dorsal root ganglia (DRG) that innervate the body or in the trigeminal ganglia (TG) that innervate the face. They send afferents to peripheral tissues such as the skin where molecular receptors located on sensory terminals react to noxious stimuli. This information is relayed to the CNS via central afferents, which synapse with second-order neurons in the spinal cord. Pathological pain is often associated with elevated nociceptor excitability. This can occur following tissue injury, which prompts an inflammatory response including the release of molecules that act to sensitize nociceptor activity and evoke pain hypersensitivity or hyperalgesia (Fig. 1A) . Damage to the peripheral nerve itself can lead to ecotopic nociceptor activity in which pain occurs in the absence of noxious stimuli. The receptors for noxious stimuli often have a Primary sensory nociceptors (blue) respond to tissue damage caused by noxious thermal, mechanical, or chemical stimuli and contribute to the inflammatory response. In addition to sending painful signals to the spinal cord and then the brain, primary nociceptors release neuropeptides such as CGRP and Substance P, which act on peripheral tissues to stimulate vasodilation, vascular leakage, and promote the release of inflammatory mediators such as protons, NGF, bradykinin, lipids, prostaglandins, and ATP (also known as the inflammatory soup; colorful spheres), which in turn promote the sensitization of the nociceptor where the threshold of activation of these neurons by physical or chemical stimuli is lowered. (B) Pain and coding by thermoTRP receptors. Noxious stimuli and temperatures activate thermoTRP receptors. TRPM8 is activated by cold (<26°C) and cooling compounds such as menthol. TRPV1 is activated by noxious heat (43°C), vanilloids such as capsaicin, and acidic pH, while TRPA1 is activated by a wide variety of pungent compounds including AITC, cinnamaldehyde (the pungent compound of cinnamon), and allicin, the active ingredient of garlic. Co-expression of TRPV1 and TRPM8 has been reported (violet neurons) as well as co-expression of TRPV1 and TRPA1 (magenta neurons). fairly restricted expression pattern, which could theoretically limit the potential for serious side effects caused by compounds that target their activity.
Initially identified as temperature-sensitive receptors, thermoTRPs, members of the transient receptor potential family of nonselective cation channels, are activated by a wide range of noxious stimuli. TRP channels are tetramers composed of identical subunits, which have six transmembrane domains and cytoplasmic amino and carboxy termini. A role for TRP channels and noxious sensation arose with the discovery of the first identified thermoTRP, TRPV1, activated by noxious stimuli such as capsaicin, the pungent ingredient in chili peppers and noxious heat (Caterina and others 1997) . In this review, we will discuss the properties of TRPV1, cool activated TRPM8, and noxious chemical activated TRPA1, as well as three thermoTRPs (TRPM3, TRPV3, and TRPV4) that are expressed in somatosensory neurons or in the case of TRPV3 peripheral targets of these nerves and their function in nociception ( Fig. 1B ).
TRPV1
TRPV1 Activation and Structure TRPV1 was first identified by its responsiveness to capsaicin, a vanilloid derived from chili peppers that elicits a burning sensation. Remarkably, TRPV1 also responded to noxious heat, with an activation threshold of approximately 43°C and a temperature coefficient of Q 10 > 20, as well as extracellular acidification, indicating it might act as a polymodal nociceptor integrating multiple forms of noxious stimuli (Caterina and others 1997) . TRPV1 has subsequently been found to respond to other pungent chemicals and endogenous lipid-derived molecules, many of which act cooperatively to stimulate channel activity. For instance, capsaicin and acidification both lower the heat activation threshold for the channel activation (Tominaga and others 1998) . Immunohistochemical analysis showed that TRPV1 is expressed in approximately 30% to 50% of all somatosensory neurons in rodent models, predominantly peptidergic C-fiber nociceptors (Tominaga and others 1998) . Knockout studies have confirmed a role for TRPV1 in nociception. Recordings from isolated DRG cells of TRPV1 knockout mice as well as behavioral analyses demonstrate significant impairments in the detection of noxious heat and protons along with complete loss of capsaicin sensitivity (Caterina and others 2000; Davis and others 2000) .
Recent single-particle cryo-EM structural analyses have revealed the structure of TRPV1 at a remarkable 3.4 angstrom resolution. Similar to voltage-gated K + and Na + channels (VGCs), TRPV1 is a tetramer that exhibits radial symmetry around a central ion channel that is formed by transmembrane segments 5-6 (S5-S6) and the intervening pore loop and is flanked by S1-S4 domains ( Fig. 2) (Liao and others 2013) . Unlike VGCs, S1-S4 domains remain stationary during activation; however, major structural rearrangements in the pore helix and selectivity filter, along with the dilation of a lower gate have been reported, suggesting a dual gating mechanism. Furthermore, pharmacological manipulation along with cryo-EM results indicate that these upper and lower gates are allosterically coupled, likely via the pore helix, which may underlie integration of the wide array of noxious signals that TRPV1 processes (Cao and others 2013b) .
Many studies have set out to better understand the ability of TRPV1 to respond to noxious stimuli. Chimeric channels created between vanilloid-sensitive and vanilloid-insensitive variants of TRPV1 have demonstrated that residues in transmembrane segments S2-S4 are required for vanilloid sensitivity including a single amino acid substitution (I550T) that was able to confer capsaicin sensitivity to capsaicin-insensitive rabbit TRPV1 (Gavva and others 2004; Johnson and others 2006; Jordt and Julius 2002) . Cryo-EM analysis revealed that vanilloids bind TRPV1 in a hydrophobic pocket composed of the outer surface of the S3-S4 helices, S4-S5 linker, and S6 helix (Cao and others 2013b) . Mutation analysis also revealed amino acid residues required for proton sensitivity. The glutamate residue E648 found between the selectivity filter and S6 mediates agonist effects of protons, whereas E600 was found to mediate the ability of protons to potentiate the activity of other TRPV1 agonists (Jordt and others 2000) . Whole-cell recordings of TRPV1 and proton-insensitive TRPV2 chimeric channels also revealed residues in the pore helix as well as in the region linking S3-S4 as necessary for responding to acidic pH (Ryu and others 2007) .
Studies utilizing reconstituted TRPV1 in artificial membranes have demonstrated that TRPV1 is intrinsically temperature sensitive and large changes in enthalpy accompany temperature-evoked activation, suggesting that conformational changes accompany temperatureevoked gating (Cao and others 2013a). The C-terminal domain, the pore forming region of TRPV1, and the N terminal region have been implicated in the heat sensitivity of the channel, and recently, it was found that PKCβII phosphorylation of T705 is required for TRPV1 thermal sensitivity (Brauchi and others 2006; Grandl and others 2010; Li and others 2014; Yang and others 2010; Yao and others 2011) . However, it is not understood how TRPV1 is able to undergo a conformational change in response to heat. Importantly, along with several other TRP channels, TRPV1 has been shown to be weakly voltage dependent such that agonists, including temperature, shift this voltage dependence toward physiological membrane potentials, suggesting that voltage may still be essential for their gating versatility (Nilius and others 2005) .
TRPV1 Modulation
TRPV1 activity is sensitized via coupling with second messenger signaling cascades by a variety of proalgesic and proinflammatory agents including nerve growth factor (NGF), bradykinin, lipids, prostaglandins, and ATP (Caterina and others 1997; Tominaga and others 1998) . Furthermore, TRPV1 activity contributes to neurogenic inflammation in which nociceptors themselves release inflammatory mediators, thus acting cell autonomously to promote inflammation and hyperalgesia ( Fig. 1B ) (Julius 2013). Analysis of knockout mice has shown that TRPV1 is required for development of inflammatory thermal hyperalgesia, demonstrating an essential role for TRPV1 in pain hypersensitivity associated with chronic pain conditions (Caterina and others 2000; Davis and others 2000) .
How do signaling molecules activated by inflammatory mediator signaling cascades modulate TRPV1 activity? Regulation of the phosphorylation state of TRPV1 has been shown to profoundly contribute to its ability to respond to noxious stimuli. Dephosphorylation of TRPV1 has been shown to cause channel desensitization following activation, whereas protein kinases including PKA and PKC, stimulated downstream of inflammatory mediators, have been shown to phosphorylate TRPV1 and reverse channel desensitization contributing to sustained channel activation ( Numerous studies have found that the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ) can also modulate TRPV1 activity. However, there has been much debate over whether it acts to potentiate or inhibit TRPV1 activity (Cao and others 2013a; Prescott and Julius 2003; Ufret-Vincenty and others 2011; Yao and Qin 2009). A possible explanation for the discrepancies between these findings comes from a recent study that found that PIP 2 had opposite effects on TRPV1 function depending on which leaflet of the cell membrane PIP 2 is inserted in; insertion into the inner leaflet led to potentiation of capsaicin-activated responses, whereas insertion into the extracellular leaflet led to inhibition (Senning and others 2014) .
TRPV1 in Pain Conditions
Many studies have shown a strong link between TRPV1 and inflammatory pain. Studies in humans found an increase in the number of TRPV1 immunoreactive fibers in inflamed skin that correlates with inflammatory hyperalgesia (Gopinath and others 2005) . Antagonists of TRPV1 have been shown to inhibit thermal and/or mechanical hypersensitivity associated with multiple models of inflammation including UVB-evoked sensitization, complete Freund's adjuvant (CFA)-induced pain, postoperative pain, and bone cancer pain in both rodent and humans (Chizh and others 2007; Honore and others 2005) . In multiple rodent models of arthritis, nocifensive behavior was significantly reduced in TRPV1 knockout animals or via treatment with TRPV1 antagonists (Barton and others 2006; Keeble and others 2005; Kelly and others 2015) . Furthermore, TRPV1 was found mediate nociception induced by activation of the inflammatory mediator, protease-activated receptor-2 (PAR 2 ), in a rodent model of joint inflammation (Helyes and others 2010; Russell and others 2012) . Thermal hyperalgesia associated with ischemic pain may also be dependent on TRPV1 (Kwon and others 2014) . TRPV1 also appears to play a pivotal role in the pain associated with inflammatory diseases of the gastrointestinal tract. Increased TRPV1 expression has been found in patients suffering from inflammatory bowel disease and functionally correlates with visceral pain hypersensitivity (Akbar and others 2008; Van Wanrooij and others 2014). TRPV1 was also observed to have increased expression, promote neurogenic inflammation, and mediate nociception in rodent models of pancreatitis (Hutter and others 2005; Xu and others 2007) .
Evidence also points to TRPV1 being functionally significant in neuropathic pain conditions. TRPV1 expression increased following nerve injury, whereas blockade of TRPV1 function reduced both thermal and/or mechanical hypersensitivity (Urano and others 2012; Watabiki and others 2011). Chemotherapeutics such as oxaliplatin or paclitaxel increase TRPV1 sensitivity, suggesting an instructive role in chemotherapy-induced peripheral neuropathy (Anand and others 2010; Chen and others 2011b; Ta and others 2010). Desensitization of TRPV1, using capsaicin and resiniferatoxin creams, patches, or injections, has been shown to provide relief from osteoarthritis, postoperative pain, and in a spinal nerve ligation (SNL) model of nerve injury-induced heat sensitivity, further supporting an involvement of TRPV1 in both in inflammatory and neuropathic pain (Backonja and others 2008; Forst and others 2002; King and others 2011; Remadevi and Szallisi 2008) .
While TRPV1 antagonists have been essential in better understanding the roles of TRPV1 and have shown promise in treating patients with neurogenic and inflammatory diseases, the development of these drugs has not come without obstacles. Common side effects of firstgeneration TRPV1 antagonists include loss of noxious heat sensation, increased burn risk, and hyperthermia (Gavva and others 2008; Krarup and others 2011; Szolcsányi and Sándor 2012) . Fortunately, several compounds have been found that differentially affect the channel. For instance, some block capsaicin, but not heat activation, suggesting that it could be feasible to separate the analgesic effects of TRPV1 antagonists from harmful side effects (Lehto and others 2008) . Indeed, second-generation antagonists such as AMG8562, APHC1, APHC3, and A-1165442 have already been tested for several inflammatory conditions with success in pain reduction while avoiding hyperthermia (Andreev and (Zakharian and others 2010) . A clear picture of structural changes that occur during cool activation is still in development. TRPV1-TRPM8 chimeras showed that the C-terminus contains structural determinants necessary for temperature activation of the channel (Brauchi and others 2006) . Mutational analyses have identified residues required for ligand activation (Fig. 3A) . Mutations in the S2 domain (Y745H) and in the C-terminal TRP domain (L1005R, L1009R) disrupt menthol and icilin sensitivity without affecting cold sensitivity. The S2 domain is most likely involved in ligand binding, whereas the TRP domain is most likely required for coupling ligand binding to channel opening (Bandell and others 2006) . Residues in the S2-S3 linker and S3 domain are necessary for icilin activation of TRPM8 (Chuang and others 2004) . The S3 domain is also required for ligand activation of TRPV1, indicating there could be a partial conservation of mechanism among thermoTRPs. Like TRPV1, TRPM8 exhibits a degree of voltage sensitivity such that thermal or menthol activation affects membrane potentials, and chargeneutralizing mutations have mapped the voltage sensor to the S4 domain and S4-S5 linker (Brauchi and others 2004; Fernández and others 2011; Voets and others 2004; Voets and others 2007) .
TRPM8 Regulation
Cold-sensitive neurons are able to acclimate to cold stimuli, which is believed to be important in cold discrimination in changing environments, and it has been suggested that these responses could be mediated by modulation of TRPM8. Activation of TRPM8 is followed by extracellular Ca 2+ -dependent desensitization, presumably via TRPM8-dependent Ca 2+ influx (McKemy and others 2002) . This process is dependent on Ca 2+ -mediated activation of phospholipase C (PLC) and subsequent depletion of PIP 2 . PIP 2 can activate TRPM8 and interacts with positive charges in the C-terminal TRP domain. Its depletion leads to reduction in TRPM8 channel activity accompanied by shifting voltage dependence toward more positive potentials (Liu and Qin 2005; Rohacs and others 2005) . As PIP 2 hydrolysis both negatively regulates TRPM8 and potentially positively regulates TRPV1, it is possible that inflammatory agents acting on PLCcoupled receptors could produce hyperalgesia by sensitizing heat responses, while decreasing any analgesic effects of innocuous cooling. Other signaling pathways in addition to PLC-PIP 2 modulate TRPM8 activity. Lysophospholipids and polyunsaturated fatty acids such as arachidonic acid are created downstream of phospholipase A 2 (PLA 2 ) activation, modulating TRPM8 positively or negatively, respectively. Interestingly, PLA 2 stimulation leads to a net suppression of TRPM8 activity (Andersson and others 2007; Bavencoffe and others 2011; Vanden Abeele and others 2006) . PKA and PKC, which act as positive regulators of TRPV1, negatively modulate TRPM8 function (Abe and others 2006; De Petrocellis and others 2007; Premkumar and others 2005) . Direct inhibition of TRPM8 by Gαq occurs downstream of the inflammatory mediators bradykinin and histamine (Zhang and others 2012) . These findings suggest that inflammatory mediators might potentiate TRPV1-dependent nociception while simultaneously inhibiting potential analgesic effects of TRPM8 dependent cooling.
TRPM8 Involvement in Pain and Analgesia
Knockout studies demonstrate that TRPM8 −/− mice exhibit complete loss of acute innocuous cold sensation, impaired responses to noxious cold temperatures, and deficits in nocifensive responses to cooling compounds The membrane protein Pirt has also been shown to regulate TRPM8. Pirt binds directly to TRPM8 and enhances the temperature and menthol threshold for TRPM8, and Pirt knockout mice exhibit impaired behavioral responses to both cold and cooling agents (Tang and others 2013) . Taken together these data strongly implicate TRPM8 in cold nociception.
Subpopulations of TRPM8+ neurons respond to different thermal thresholds, suggesting that distinct neurons differentiate innocuous and noxious cold sensations (McKemy 2013). Studies with TRPM8-reporter mouse lines have revealed that ~10% to 30% of TRPM8 expressing neurons coexpress TRPV1, suggesting that there are at least two populations of TRPM8-expressing neurons: a TRPM8 only population for innocuous cool sensation and a TRPM8+/TRPV1+ population required for noxious cold sensation (Fig. 3B ). Consistent with this idea, the number of TRPM8-positive neurons expressing TRPV1 rose 65% following CFA-induced inflammation (Dhaka and others 2008; Takashima and others 2007) . However, specific ablation of TRPV1+ neurons in adult mice did not alter aversion to noxious cold temperature or paw withdrawal to noxious cold temperatures, suggesting that TRPM8+/TRPV1+ neurons may be dispensable for TRPM8-mediated noxious cold behavior (Pogorzala and others 2013) .
TRPM8 also has roles in inflammatory and neuropathic cold allodynia. In both CFA-induced inflammation and chronic constrictive nerve injury (CCI) models, injury-induced hypersensitivity to the topically administered cooling agent acetone is attenuated in TRPM8 −/− mice and in animals treated with TRPM8 antagonist (Colburn and others 2007; Knowlton and others 2011; Xing and others 2007) . These results correlate with findings of increased expression of TRPM8 in rat DRG neurons after CCI (Su and others 2011). However, a conflicting study reported reduced TRPM8 expression and no changes in the functional properties of cold/menthol sensitive neurons following CCI in mice (Caspani and others 2009 ). Cold allodynia is often present in patients following chemotherapy-induced peripheral neuropathy. TRPM8 expression was found to be up-regulated following oxaliplatin treatment in mice, but oxaliplatin-induced cold allodynia was absent in TRPM8 −/− mice (Gauchan and others 2009; Knowlton and others 2011). The proalgesic glial derived growth factor artemin has also been shown to potentiate TRPM8-dependent cold hypersensitivity (Lippoldt and others 2013) . Cold allodynia follows morphine withdrawal, but is absent in TRPM8 −/− mice, and the µ opiate receptor 1 (OPRM1) has been shown to interact with and stimulate TRPM8 internalization following activation (Shapovalov and others 2013) . TRPM8 may also potentiate painful bladder syndrome (PBS). TRPM8 expression is elevated in PBS patients compared with controls, and the TRPM8 antagonist AMTB attenuated nociceptive reflexes associated with PBS (Lashinger and others 2008; Mukerji and others 2006) .
Cold or topical menthol exposure is a common method of pain relief. TRPM8 mediates some aspects of cool analgesia in addition to having a role in cold nociception. Cool mediated analgesia to an acute noxious stimulus (formalin) was absent in TRPM8 −/− mice (Dhaka and others 2007) . Activation of TRPM8, either by chemical agonists and/or cooling, caused a significant reduction in nocifensive behavior elicited by CFA-or CCI-induced thermal and/or mechanical hyperalgesia (Proudfoot and others 2006; Su and others 2011). Reversal of CCIinduced mechanical hypersensitivity by cooling was also absent in TRPM8 −/− animals (Knowlton and others 2013). Menthol-evoked analgesia, confirmed to be dependent on TRPM8, also involves endogenous opioid pathways as systemic naloxone treatment reversed TRPM8-dependent analgesia (Liu and others 2013) . Taken together, these results demonstrate that depending on context, TRPM8 functions in innocuous cool sensation, nociception, or analgesia. How TRPM8 may be able to convey these different sensory modalities is still unclear and awaits further investigation (Fig. 3B) .
Finding antagonists specific to TRPM8 may be invaluable in treating conditions such as cold allodynia. Conversely, creation of tailored TRPM8 agonists to evoke analgesia could also be useful in the development of novel therapeutics. Blockade of TRPM8 channels with small molecule antagonists reduces acute, inflammatory, and neuropathic cold pain responses in mice (Calvo and others 2012; Knowlton and others 2011; Patel and others 2014). However, similar to TRPV1 antagonists, TRPM8 antagonists alter body temperature, but in contrast to TRPV1 antagonists, they cause hypothermia (Calvo and others 2012; Knowlton and others 2011; Patel and others 2014) . Therefore, it will be necessary to develop drugs that are specific to cold nociception. Recently, a potent TRPM8 antagonist (PF-05105697) was developed that was successfully able to treat pain without causing hypothermia in humans; however, patients reported the sensation of excessive warmth ("feeling hot") as a side effect (Winchester and others 2014) .
TRPA1

TRPA1 Is Activated by a Wide Array of Inflammatory Agents
TRPA1, initially termed ANKTM1 due to the presence of multiple N-terminal ankyrin repeats, was originally characterized as a potential noxious cold detector (Fig. 4) . In vitro studies found that the channel was activated at an average threshold of 17°C coinciding with the threshold for human noxious cold detection. TRPA1 is expressed in about 30% of TRPV1 expressing peptidergic C-and/or Aδ-fibers providing support for a role for TRPA1 in nociception. These findings, however, were called into question by studies that found no evidence for cold activation of this channel (Jordt and others 2004) . While still controversial, reports utilizing TRPA1 −/− mice suggest that at least in mice, TRPA1 does not appear to play a major role in acute noxious cold sensation but may serve to potentiate injury evoked cold hypersensitivity (Del Camino and others 2010; Knowlton and others 2010; Obata and others 2005) . A recent study, however, has reported that human TRPA1 expressed in artificial membranes is intrinsically cold sensitive and opens up the possibility that TRPA1 has functional role in cold perception in humans (Moparthi and others 2014) .
There is a clear consensus that TRPA1 is a promiscuous detector of noxious chemical stimuli. TRPA1 is activated by an array of exogenous chemical irritants and endogenous agents that cause pain and inflammation. As for other thermoTRP channels, plant-based compounds function as TRPA1 agonists. Examples of these pungent compounds, which elicit burning and tingling sensations, include allyl isothiocynate (AITC, mustard/wasabi), allicin (garlic), methyl salicylate (wintergreen), and cinnamaldehyde (cinnamon) (Bandell and others 2004; Jordt and others 2004; Macpherson and others 2005) . Other toxic agents including environmental irritants such as acrolein, ozone, ammonia, formalin, zinc, and therapeutics with known painful side effects such as disulfiram and glibenclamide also serve as agonists for the channel (Babes and others 2013; Bautista and others 2006; Dhaka and others 2009; Macpherson others 2007b; Maher and others 2008; Taylor-Clark and Undem 2010) . Endogenous compounds that function as inflammatory mediators and are linked to painful inflammatory syndromes, such as 4-hydroxynonenal (4-HNE), 15-deoxy-δ(12,14)-prostaglandin J2 (15d-PGJ2), hydrogen peroxide, and hydrogen sulfide, also activate TRPA1 (Andersson and others 2008; Cruz-Orengo and others 2008; Macpherson and others 2007b; Streng and others 2008; Wang and others 2011) . A human TRPA1 gain of function mutation that causes familial episodic pain syndrome suggests a fundamental role for TRPA1 in pain perception, perhaps functioning alongside TRPV1 as critical detectors of painful stimuli (Kremeyer and others 2010) .
Many TRPA1 agonists have diverse and on first inspection seemingly unrelated chemical structures. How then could these compounds all activate this channel?
The answer for a great many of these agonists lies in their electrophilic properties (Cruz-Orengo and others 2008; Hinman and others 2006; Macpherson and others 2007b) . Instead of a shared common binding site as usually required for traditional ligand-channel interaction, it is the shared chemical reactivity of these compounds that facilitates TRPA1 activation. These electrophiles react with three cysteine residues located in the intracellular N-terminal region. Mutation of these three cysteine residues leaves TRPA1 largely insensitive to electrophiles (Hinman and others 2006; Macpherson others 2007a) . Additional residues including an N-terminal lysine and cysteines outside the N-terminus might contribute to the regulation or minimally to the activation of the channel (Fig. 4) (Zygmunt and Högestätt 2014) .
TRPA1 can also serve as a receptor-operated channel where activation or sensitization occurs through coupling with other receptors via second messenger signaling cascades. For instance, inflammatory mediators such as bradykinin or ATP can activate TRPA1 via PLC-dependent pathways downstream of their G q -protein coupled receptors (Bandell and others 2004; Jordt and others 2004) . Although it is not known what signaling molecules directly activate TRPA1, calcium, PKA, and PIP 2 have been shown to modulate channel activity (Akopian and others 2007; Doerner and others 2007; Karashima and others 2008; Kim and others 2008; Zurborg and others 2007) . Intriguingly, the toll-like receptor (TLR7) can complex with TRPA1 showing association in co-immunopreciptiation assays. Both receptors are required to elicit single-channel activity from exposure to the extracellular microRNA let-7b, which remarkably has been shown to elicit nociceptive responses in mice (Park and others 2014) .
TRPA1 and Pain
The creation of TRPA1 −/− animals and the development of potent antagonists for TRPA1 have firmly established TRPA1 as a central player in acute and inflammatory nociception. Although electrophiles modify proteins indiscriminately causing cellular/organismal damage, TRPA1 −/− mutation drastically reduces or eliminates nociceptive responses to chemicals including AITC, 4-HNE, and acrolein in knockout mice (Bautista and others 2006; Kwan and others 2006) . AITC is a known inducer of neurogenic inflammation and mechanical and thermal hyperalgesia (Bánvölgyi and others 2004; Bautista and others 2006) . Coupled with the fact that TRPA1 is primarily expressed in peptidergic C-fibers, this suggested that TRPA1 might be required for neurogenic inflammation. Investigations with TRPA1 −/− animals showed that not only is TRPA1 required for AITC-induced mechanical and thermal hyperalgesia but also for the neurogenic inflammatory response and tissue edema associated with AITC-induced inflammation (Bautista and others 2006; Moilanen and others 2012) . Other lines of evidence indicate that TRPA1 may be a key mediator in inflammatory pain. TRPA1 is required for neurogenic inflammation induced by carrageenan, a chemical commonly used to induce inflammation (Moilanen and others 2012). Its expression is increased in somatosensory neurons following CFA-induced inflammation, and inflammatory mediators modulate cell surface expression of TRPA1 (Da Costa and others 2010; Obata and others 2005). Furthermore, pharmacological blockade of TRPA1 by antagonists AP18 and/or HC-030031 inhibits CFA-evoked mechanical and cold hyperalgesia (Del Camino and others 2010; Petrus and others 2007).
TRPA1 has been implicated in a number of inflammatory disease models. In rodent models of arthritis, rodents treated with TRPA1 antagonists or TRPA1 −/− mice have shown attenuated mechanical hyperalgesia evoked by injection of TNFα, CFA, or monoiodoacetate (Fernandes and others 2011; McGaraughty and others 2010) . Activation of intestinal TRPA1 can induce acute neurogenic inflammatory pancreatitis, and TRPA1 antagonists act synergistically with TRPV1 antagonists to inhibit pancreatic pain, preventing the progression from acute to chronic pain. This suggests these two channels act in concert to promote pain in animal models of this disease (Ceppa and others 2010; Schwartz and others 2011; Schwartz and others 2013) . TRPA1 has also been implicated in pain associated with bladder hyperalgesia in a mouse model of cystitis (DeBerry and others 2014) and other models of inflammatory diseases of the gastrointestinal tract. For example, TRPA1 appears to mediate neurogenic inflammation in rodent models of colitis and contributes to visceral mechanical hypersensitivity (Engel and others 2011) . TRPA1 may be a player in neuropathic pain conditions. Following nerve injury, pharmacological blockade of TRPA1 reduced mechanical allodynia evoked by nerve injury (Eid and others 2008) . However, studies investigating nerve injury-evoked cold allodynia have provided conflicting data, perhaps due to differences in the methodology of nerve injury. Some studies have found that nerve injury increased TRPA1 expression in the DRG and cold allodynia inhibited following antisense knockdown or pharmacological blockade of TRPA1, while others found decreased TRPA1 expression and function in the DRG following nerve injury (Caspani and others 2009; Chen and others 2011a; Katsura and others 2006) . TRPA1 does seem to play an important role in chemotherapy-induced neuropathic pain. Mechanical and cold allodynia, induced by the chemotherapeutics cisplatin and oxaliplatin, are reduced in TRPA1 −/− animals or by treatment with TRPA1 antagonists (Nassini and others 2011; Zhao and others 2012) . Disease models of diabetic neuropathy strongly implicate TRPA1 in the mechanical hypersensitivity elicited by streptozotocin-induced diabetes (Wei and others 2009) . Methylglyoxal, an electrophilic compound of which production is linked to diabetic neuropathy, directly activates TRPA1 and evokes TRPA1-dependent nociceptive behavior (Andersson and others 2013).
TRPM3
While less extensively studied than other thermoTRPS, TRPM3 has been recently identified as a noxious heat receptor. TRPM3 expressing HEK293T cells exhibited strong responses to heat (40°C). TRPM3 has a fairly moderate temperature coefficient (Q 10 = 7.2), where temperature-evoked current increases gradually at temperature >15°C, compared with TRPV1 (Q 10 = 16.8), where steep activation is observed at temperatures >42°C. Like TRPV1, TRPM3 exhibits voltage sensitivity where thermal activation might shift voltage-dependent activation closer to physiological membrane potential (Vriens and others 2011) . TRPM3 is expressed in somatosensory neurons with one study showing TRPM3 expression in ~80% of these neurons, although detailed analysis of which populations of somatosensory neurons express TRPM3 remains to be determined (Nealen and others 2003; Staaf and others 2010; Vriens and others 2011) .
The neuroactive steroid pregnenolone sulfate (PS) is an agonist for TRPM3 (Wagner and others 2008) . Physiological levels of PS were found to dramatically potentiate TRPM3 activity to heat at temperatures as low as 37°C, suggesting that TRPM3 could play a role in heat sensitization. In cultured DRG neurons, roughly 60% of neurons responded to PS, and responses were limited to small-diameter neurons. About half of these neurons responded to capsaicin, indicating that there is substantial overlapping expression between TRPM3 and TRPV1. A potential role for TRPM3 in nociception was found when nocifensive behaviors elicited by PS were absent in TRPM3 −/− animals. Specific deficits in acute and inflammatory noxious heat sensation were also observed in TRPM3 −/− animals, suggesting that TRPV1 and TRPM3 might act in concert to detect noxious heat (Vriens and others 2011) . Corroborating a role for TRPM3 in noxious heat sensation, specific TRPM3 antagonists isosakuranetin and hesperetin significantly inhibited noxious heat and PS-induced nociception (Straub and others 2013).
TRPV3
There is conflicting evidence supporting a significant role for the warm/camphor-activated channel TRPV3 in thermal nociception. TRPV3, which shares 40% homology with TRPV1, has a thermal threshold of 33°C and exhibits increasing responses as temperatures elevate into the noxious range (Peier and others 2002b) . In rodents, TRPV3 is primarily expressed in skin keratinocytes as well as other epithelia of the tongue, palate, nose, and distal colon. However, TRPV3 is not expressed in rodent sensory neurons, though mRNA and protein analysis in monkey and human have reported that TRPV3 expression in sensory neurons of these species (Smith and others 2002; Xu and others 2002) . If accurate, TRPV3 may function to detect temperature differently in rodents and primates. The restricted expression of TRPV3 to epithelial cells suggests that any role the channel could have in thermal sensation and/or nociception would likely be indirect through a relay of information between these cells and sensory neurons.
Studies utilizing TRPV3 −/− mice have reported conflicting findings. Some studies reported nocifensive deficits in response to noxious heat suggesting overlapping function between TRPV1 and TRPV3, while others reported no deficits in noxious heat sensation (Huang and others 2011; Marics and others 2014; Miyamoto and others 2011; Moqrich and others 2005) . Differences in mouse strain background or methodology may account for the conflicting findings. The group that reported differences in heat sensation found that TRPV3 activation led to nitric oxide (NO) production in keratinocytes and blockade of NO synthesis inhibited acute thermal nociception via a TRPV3 dependent mechanism. Evidence was also provided suggesting that NO acts upstream of TRPV1 to evoke thermal nocifensive behavior (Miyamoto and others 2011) .
Although knockout studies did not support a role for TRPV3 in inflammatory thermal hyperalgesia, other studies described a link. When TRPV3 was overexpressed in keratinocytes, these cells released the inflammatory mediator, prostaglandin E(2) (PGE(2)), in a TRPV3-dependent manner. Inhibition of PGE(2) production, with co-inhibition of TRPV1 to mask its contributions to thermal hyperalgesia, decreased inflammatory thermal hyperalgesia in mice overexpressing TRPV3 in keratinocytes (Huang and others 2008) . TRPV3 activation in keratinocytes has also been linked to the production and release of the inflammatory mediator ATP, suggesting another TRPV3-dependent route to sensitize nociceptive pathways (Mandadi and others 2009 ). The endogenous TRPV3 antagonist 17(R)-resolvin D1 was found to reverse inflammatory thermal hyperalgesia, and this effect was blunted on knockdown of epidermal TRPV3 expression (Bang and others 2012) further support for a role for TRPV3 in inflammatory nociception.
TRPV4
Like TRPV3, TRPV4 is activated by warm temperatures (25-34°C) (Guler and others 2002; Watanabe and others 2002) . Unlike TRPV3, which is strongly sensitized by repeated heat activation, TRPV4 is desensitized on sustained or repeated stimulation at temperatures ≥42°C (Guler and others 2002) . PIP 2 is required for thermal activation of TRPV4, as mutation of its N-terminal phosphoinositide binding site inhibits activation (Garcia-Elias and others 2013). A tyrosine in its S3 domain has also been shown to be required for thermal sensitivity (Vriens and others 2004) . TRPV4 is also activated by osmotic stimuli. Hypotonic solution activates the channel whereas hypertonic solution inhibits its activity (Liedtke and others 2000; Strotmann and others 2000) . Mechanical shear stress and high-viscosity solutions have also been reported to activate TRPV4. The channel is broadly expressed in many tissues including keratinocytes and sensory neurons (Everaerts and others 2010) . Within sensory neurons there is evidence that TRPV4 is expressed in small-/mediumdiameter neurons with overlap in expression with TRPV1 (Alessandri-Haber and others 2003).
TRPV4 −/− mice were reported to have impaired nocifensive responses to a number of stimuli including mechanical stimuli, mild hypertonic solution, and hypotonic solution (Alessandri-Haber and others 2003; Liedtke and Friedman 2003; Suzuki and others 2003) . There are conflicting reports on the role of TRPV4 in noxious heat sensation. Some studies showed no effects on temperature sensation, normal acute responses to noxious heat but impaired inflammatory thermal hyperalgesia, while others showed deficits in acute heat responses yet no differences in behavior after inflammation (Huang and others 2011; Lee and others 2005; Liedtke and Friedman 2003; Suzuki and others 2003; Todaka and others 2004) . Additionally, inflammatory mediators such as PGE 2 and PAR 2 have been shown to sensitize TRPV4 (Alessandri-Haber and others 2005; Grant and others 2007; Zhao and others 2014). These results indicate that TRPV4 could be required for normal nociception and could have a role in abnormal pain conditions. Indeed, in a rodent model of chemotherapyinduced neuropathic pain, antisense oligonucleotide knockdown of TRPV4 in sensory neurons inhibited mechanical and hypotonic hyperalgesia (Alessandri-Haber and others 2004). TRPV4 as well as TRPV1 were shown to be required for mechanical hypersensitivity associated with delayed onset muscle soreness (Ota and others 2013) . TRPV4 and TRPA1 were both found to contribute to formalin-evoked trigeminal pain (Chen and others 2014). TRPV4 plays a pivotal role in pain associated with a model of temporomandibular joint disorder, as TRPV4 −/− animals display reduced masticatory sensitization . Although these data implicate TRPV4 as a mediator of nociception, widespread expression in many tissues might limit its usefulness as a target for analgesic intervention.
Conclusions
Despite massive investment, there has been limited success in the development of effective analgesics for the treatment of chronic pain. It is now clear in the 18 years since the discovery of TRPV1 that thermoTRP channels play an essential role as primary molecular sensors of noxious stimuli and are integral to pain elicited by inflammatory and neuropathic pain conditions. Whether or not thermoTRPs will be useful targets for analgesic intervention remains to be seen. Antagonists of thermoTRPs, while successfully inhibiting pain caused by inflammatory and chronic pain diseases, have had unforeseen side effects including body temperature dysregulation and blockade of acute thermal sensation used to avoid injury. Promising new studies suggest that these obstacles may be able to be overcome with more specific drugs. It is always difficult to translate research from the bench to the clinical settings but thermoTRPs remain enticing targets for pain intervention.
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